ZP
MLTX icon

Zimmer Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Zimmer Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,960
Closed -$329K – 181
2025
Q2 		$329K Sell
6,960
-17,540
-72% -$714K 0.01% 147
2025
Q1 		$957K Buy
+24,500
New +$1.06M 0.02% 162

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Zimmer Partners's MLTX Position: Q3 2025 in Review

Zimmer Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 6,960 shares — an estimated $329K sold.

Zimmer Partners first reported a position in MLTX in Q1 2025 and held it in 2 quarters. The position peaked at $957K in Q1 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Zimmer Partners reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Zimmer Partners sold 6,960 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $329K.
  • Zimmer Partners first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 2 quarters.
  • Zimmer Partners's MoonLake Immunotherapeutics position peaked at $957K in Q1 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Zimmer Partners's 13F filing for Q3 2025, filed 14 Nov 2025.